Prevnar News and Research

RSS

MSU team creates a promising vaccine candidate for antibiotic-resistant bacteria

Driven by the overuse of antimicrobials, pathogens are quickly building up resistances to once-successful treatments.

24 Apr 2024

Study highlights impact of government vaccine recommendations and direct-to-consumer pharmaceutical advertising

A new study co-authored by a University of Massachusetts Amherst economist reveals the value of government vaccine recommendations to drugmakers, as well as potential benefits of advertising pharmaceuticals directly to consumers -; a practice that is banned in every country apart from the United States and New Zealand.

13 Mar 2024

New technology can provide immunization against infectious diseases

A single-use, self-administered microneedle technology developed by UConn faculty to provide immunization against infectious diseases has recently been validated by preclinical research trials.

23 Nov 2020

Time to discuss potentially unpleasant side effects of COVID shots? Scientists say yes.

Drugmaker Pfizer is expected to seek federal permission to release its COVID-19 vaccine by the end of November, a move that holds promise for quelling the pandemic, but also sets up a tight time frame for making sure consumers understand what it will mean to actually get the shots.

12 Nov 2020

Vaccine reduces race-based pneumococcal disease disparities

In a major public health success, the introduction of pneumococcal conjugate vaccine PCV13, or Prevnar 13, in 2010 in the United States is associated with reduction in socioeconomic disparities and the near elimination of Black-white-based racial disparities for invasive pneumococcal disease.

31 Aug 2020

Recommending adults to get pneumococcal vaccine at age 50 may be effective guidance

If mitigating racial disparities in those who contract pneumococcal diseases, such as meningitis and pneumonia, is a top public health priority, then recommending that all adults get a pneumococcal vaccine at age 50 would likely be effective guidance, according to a University of Pittsburgh School of Medicine analysis published today in the journal Vaccine.

4 Mar 2019

The ratcheting cost of the pneumococcal vaccine: What gives?

Every November, like clockwork, she gets the same letter, said Dr. Lindsay Irvin, a pediatrician in San Antonio.

29 Nov 2017

New vaccine for pneumonia holds promise to save thousands of lives

In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.

20 Oct 2017

One-shot vaccine passes key preclinical test in newborn monkey models

Newborns are highly vulnerable to infections and don't respond optimally to most vaccines because their young immune systems typically mount weak antibody responses.

24 Mar 2017

Important vaccines that should not be missed by adults, elders and pregnant women

Vaccines are an important part of routine healthcare for adults, seniors and women who are pregnant.

16 Jan 2017

Medical advisory panel recommends new pneumonia vaccine for seniors

The experts expressed concern, however, that Medicare rules may hamper some people from getting the new vaccine if they have already had an older version. Also in drug issues, some patient advocates report that insurers are balking at paying for a costly drug to treat hepatitis C if the patients are in drug treatment programs.

15 Aug 2014

Prevalence of bacterial meningitis drops in the United States

Advances in the prevention and treatment of an often fatal condition called bacterial meningitis appear to be paying dividends in the United States, report infectious disease experts at The University of Texas Health Science Center at Houston (UTHealth) in the journal The Lancet Infectious Diseases.

13 Aug 2014

Astellas, ClearPath announce strategic partnership to develop vaccine for infectious diseases

Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases.

6 Jan 2014

Genocea commences GEN-004 Phase 1 study to prevent pneumococcus infections

Genocea Biosciences, Inc., a clinical-stage company pioneering novel T cell vaccines, announced today that it has initiated a Phase 1 study of GEN-004, an investigational vaccine candidate for pneumococcus (Streptococcus pneumoniae), a major cause of infectious disease-related death globally. GEN-004 is the first vaccine candidate designed to prevent infections caused by all strains of pneumococcus through a novel T cell-mediated mechanism of action.

5 Dec 2013

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease.

18 Oct 2013

Infant vaccination against pneumonia helps protect elderly

Children who receive a vaccine to prevent blood and ear infections, appear to be reducing the spread of pneumonia to the rest of the population, especially their grandparents and other older adults.

11 Jul 2013

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer Inc. announced today the company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), received European approval for an expanded indication to include adults aged 18 to 49 years for active immunization for the prevention of invasive disease caused by vaccine-type Streptococcus pneumoniae (S. pneumoniae).

10 Jul 2013

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pfizer Inc. presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age.

From Pfizer, Inc. 29 Apr 2013

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Pfizer Inc. presented today the results from a Phase 3 study demonstrating the immunogenicity, tolerability and safety of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine Diphtheria CRM197 Protein)in adults infected with human immunodeficiency virus (HIV).

5 Mar 2013

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.

28 Jan 2013